AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Patent Granted For DNA Vaccine Technology.(Brief Article)
2001 APR 18 - (NewsRx.com & NewsRx.net) --
The Immune Response Corp. (IMNR) announced March 30, 2001, that it has received U.S. Patent Number 6,207,645 expanding coverage relating to its immune-based therapy for rheumatoid arthritis, Ravax(TM).
The recently issued patent has specific claims covering immunization using DNA vaccines that are designed to synthesize the T-cell receptor (TCR) V(beta) specific peptides in situ, in contrast to immunizing directly with the TCR peptides themselves. The patent also includes specific claims for DNA vaccines encoding key superantigen protein sequences from the V(beta) 3, V(beta) 14, and V(beta) 17 regions of the TCR present on the surface of these pathogenic T cells thought to be associated with rheumatoid arthritis.
The company believes that vaccination with Ravax may inhibit the disease-associated T cells that cause rheumatoid arthritis, and prevent further damage in patients suffering from the disease.
"This recent issuance is a key patent in that it extends previous coverage ...
- The Immune Response Corp. (Earnings)
- Magazine article from: San Diego Business Journal August 5, 1991 700+ words
The Immune Response Corp. The Immune Response Corp. lost $927,000, or 7 cents a share, on research revenue of $1.1 million for the second quarter ending June 30. That compares to income of $566,000, or 2 cents a share, on research...
- THE IMMUNE RESPONSE CORP. ANNOUNCES THIRD QUARTER 1991 FINANCIAL RESULTS
- Press release article from: PR Newswire November 6, 1991 700+ words
THE IMMUNE RESPONSE CORP. ANNOUNCES THIRD QUARTER 1991...Nov. 6 /PRNewswire/ -- The Immune Response Corp. (NASDAQ-NMS: IMNR) today...operating results of the company. The Immune Response Corp. is a biopharmaceutical company...
- The Immune Response Corp. to Present at Wall Street Analyst Forum 51st NYC...
- Press release article from: Business Wire February 24, 2004 700+ words
...BUSINESS WIRE)--Feb. 24, 2004 The Immune Response Corp. (NASDAQ: IMNR), a biopharmaceutical...s Web site for 30 days. About The Immune Response Corp. and REMUNE(R) The Immune Response Corp. is developing immune-based therapies...
- The Immune Response Corp. to Present at Institutional Investors Forum 2004.
- Press release article from: Business Wire February 20, 2004 700+ words
...BUSINESS WIRE)--Feb. 20, 2004 The Immune Response Corp. (NASDAQ: IMNR), a biopharmaceutical...s Web site for 30 days. About The Immune Response Corp. and REMUNE(R) The Immune Response Corp. is developing immune-based therapies...
- The Immune Response Corp. files proposed initial public offering of 2,200,000...
- Press release article from: PR Newswire April 2, 1990 700+ words
THE IMMUNE RESPONSE CORP. FILES PROPOSED INITIAL PUBLIC...April 2 /PRNewswire/ -- The Immune Response Corp. announced that on March 30...New York, NY 10022. The Immune Response Corp. is a biopharmaceutical company...
- THE IMMUNE RESPONSE CORP. DISCOVERS T CELLS INVOLVED IN RHEUMATOID ARTHRITIS
- Press release article from: PR Newswire December 2, 1991 700+ words
THE IMMUNE RESPONSE CORP. DISCOVERS T CELLS INVOLVED IN...Dec. 2 /PRNewswire/ -- The Immune Response Corp. (NASDAQ/NMS: IMNR) announced...from rheumatoid arthritis. The Immune Response Corp. is a biopharmaceutical company...
- The Immune Response Corp. reports third-quarter 1990 financial results.
- Press release article from: PR Newswire November 6, 1990 700+ words
THE IMMUNE RESPONSE CORP. REPORTS THIRD QUARTER 1990 FINANCIAL...Nov. 6 /PRNewswire/ -- The Immune Response Corp. (IRC) (NASDAQ: IMNR) today...its HIV Immunotherapeutic. The Immune Response Corp. is a biopharmaceutical company...
- The Immune Response Corp. makes initial public offering of 2,200,000 shares of...
- Press release article from: PR Newswire May 2, 1990 700+ words
THE IMMUNE RESPONSE CORP. MAKES INITIAL PUBLIC OFFERING...May 2 /PRNewswire/ -- The Immune Response Corp. (NASDAQ: IMNR) announced...Avenue, New York, NY 10022. The Immune Response Corp. is a biopharmaceutical company...
Source: HighBeam Research, Patent Granted For DNA Vaccine Technology.(Brief Article)